The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
ApexOnco Front Page
Recent articles
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
Summit and Nuvalent have scored prized plenary spots.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Inclacumab fails, and osivelotor is on hold.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
